Russell Investments Group
FDMT icon

Russell Investments Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Russell Investments Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Buy
23,459
+20,316
+646% +$198K ﹤0.01% 3004
2026
Q1 		$29.3K Sell
3,143
-267
-8% -$2.32K ﹤0.01% 3499
2025
Q4 		$25.6K Hold
3,410
– – ﹤0.01% 3541
2025
Q3 		$29.6K Sell
3,410
-18,406
-84% -$110K ﹤0.01% 3469
2025
Q2 		$80.9K Buy
21,816
+2,284
+12% +$8.03K ﹤0.01% 2875
2025
Q1 		$63.1K Buy
+19,532
New +$92K ﹤0.01% 2852
2024
Q4 		– Sell
-175
Closed -$1.89K – 3729
2024
Q3 		$1.89K Sell
175
-2,133
-92% -$35.4K ﹤0.01% 3384
2024
Q2 		$48.4K Buy
+2,308
New +$57.9K ﹤0.01% 2770
2023
Q4 		– Sell
-16
Closed -$204 – 3238
2023
Q3 		$204 Sell
16
-1,110
-99% -$18.6K ﹤0.01% 3495
2023
Q2 		$20.3K Hold
1,126
– – ﹤0.01% 2838
2023
Q1 		$19.4K Sell
1,126
-443
-28% -$8.61K ﹤0.01% 2817
2022
Q4 		$34.8K Hold
1,569
– – ﹤0.01% 2759
2022
Q3 		$12K Buy
+1,569
New +$14.2K ﹤0.01% 2849
2022
Q2 		– Sell
-742
Closed -$11K – 2914
2022
Q1 		$11K Sell
742
-56,197
-99% -$883K ﹤0.01% 2705
2021
Q4 		$1.25M Sell
56,939
-45,778
-45% -$1.12M ﹤0.01% 2041
2021
Q3 		$2.77M Buy
+102,717
New +$2.93M ﹤0.01% 1633

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Russell Investments Group's FDMT Position: Q2 2026 in Review

Russell Investments Group increased its 4D Molecular Therapeutics (FDMT) stake by 646% in Q2 2026, buying an estimated $198K and bringing the position to 23,459 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #3004.

Russell Investments Group first reported a position in FDMT in Q3 2021 and has held it in 16 quarters since. The position peaked at $2.77M in Q3 2021. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Russell Investments Group held 23,459 shares of 4D Molecular Therapeutics worth $312K as of Q2 2026.
  • Russell Investments Group bought 20,316 4D Molecular Therapeutics shares in Q2 2026, an estimated $198K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3004 holding.
  • Russell Investments Group first reported a position in 4D Molecular Therapeutics in Q3 2021 and has held it in 16 quarters since.
  • Russell Investments Group's 4D Molecular Therapeutics position peaked at $2.77M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.